DexCom (DXCM) Rating Lowered to Sell at ValuEngine
ValuEngine cut shares of DexCom (NASDAQ:DXCM) from a hold rating to a sell rating in a research note published on Thursday morning.
Several other research analysts have also recently issued reports on the company. BidaskClub cut DexCom from a strong-buy rating to a buy rating in a research report on Thursday, January 18th. Northland Securities reaffirmed a sell rating and set a $40.00 price objective on shares of DexCom in a research report on Tuesday, January 16th. Barclays reaffirmed a hold rating and set a $60.00 price objective on shares of DexCom in a research report on Monday, January 8th. Jefferies Group upped their target price on DexCom from $58.00 to $70.00 and gave the company a buy rating in a research report on Friday, December 22nd. Finally, BMO Capital Markets upped their target price on DexCom to $74.00 and gave the company an outperform rating in a research report on Tuesday, December 12th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $68.50.
DexCom (DXCM) opened at $54.35 on Thursday. The stock has a market capitalization of $4,720.00, a PE ratio of -95.35 and a beta of 0.21. DexCom has a 1 year low of $42.62 and a 1 year high of $86.32. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.
Several hedge funds have recently modified their holdings of the company. FDx Advisors Inc. raised its stake in shares of DexCom by 33.3% during the 4th quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock worth $1,324,000 after buying an additional 5,764 shares in the last quarter. American International Group Inc. purchased a new position in shares of DexCom during the 4th quarter worth approximately $116,000. Wedbush Securities Inc. raised its stake in shares of DexCom by 24.2% during the 4th quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock worth $321,000 after buying an additional 1,089 shares in the last quarter. Capital Fund Management S.A. purchased a new position in shares of DexCom during the 4th quarter worth approximately $5,013,000. Finally, D.A. Davidson & CO. purchased a new position in shares of DexCom during the 4th quarter worth approximately $208,000.
ILLEGAL ACTIVITY NOTICE: “DexCom (DXCM) Rating Lowered to Sell at ValuEngine” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/dexcom-dxcm-rating-lowered-to-sell-at-valuengine/1860115.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.